MediWound Ltd.
MediWound develops and commercializes biologic therapies for wound and burn care, focusing on enzymatic tissue repair and debridement. Its products are intended for patients with thermal burns and chronic or hard-to-heal wounds. MediWound’s flagship product, NexoBrid, is a topical biological drug that removes burn eschar while preserving viable tissue and is approved in more than 45 countries. EscharEx is a topical enzymatic therapy in Phase III development for venous leg ulcers, with studies also planned for diabetic foot and pressure ulcers. Its pipeline includes MW005, a topical treatment for basal cell carcinoma. MediWound manufactures NexoBrid and product candidates at its cGMP certified sterile facility at its headquarters in Yavne, Israel. It makes money through commercialization of NexoBrid and development services under government contracts, including contracts with BARDA and the DoW and MTEC.
No SEC Form 4 filings for $MDWD in the last 30 days.
See all $MDWD insider activity →MediWound (MDWD) announced a share sale of 1.2 million ordinary shares, with H.C. Wainwright & Co. as underwriter. The deal is expected to close around Nov. 5, 2026, with gross proceeds estimated at approximately $30 million, assuming no exercise of the underwriter’s option. The company plans to use the net proceeds for working capital and general corporate purposes.
MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.
MediWound (MDWD) reported that a DSMB review recommended continuing the Phase III VALUE study of EscharEx for venous leg ulcers without modifications, citing no safety concerns. The trial aims to enroll 216 patients, with completion expected by Q1 2027. MDWD's stock closed at $13.11 on September 11, 2026, and is up 2.21% in pre-market trading.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MDWD (MediWound Ltd.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent MDWD coverage spans financial news, insider activity and corporate actions.
The equity raise will increase shares outstanding and provide cash for working capital, likely creating short‑term dilution pressure.
The award validates the product and may lift MDWD’s share price as investors price in additional government backing.
Positive safety endorsement may reduce risk perception and support upside potential.
Reaffirmed 2026 revenue range with trial progress, but YoY revenue softness tied to BARDA timing suggests near-term visibility risk.
Earnings miss revenue expectations, but guidance unchanged; modest negative sentiment.
AlphAI scores every news story that mentions MDWD with an AI model for sentiment and relevance, and aggregates insider trades from MediWound Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MediWound (MDWD) announced a share sale of 1.2 million ordinary shares, with H.C. Wainwright & Co. as underwriter. The deal is expected to close around Nov. 5, 2026, with gross proceeds estimated at approximately $30 million, assuming no exercise of the underwriter’s option. The company plans to use the net proceeds for working capital and general corporate purposes.
MediWound (MDWD) received a $3.3M award from the U.S. Department of War to develop a room-temperature-stable version of its burn treatment gel, NexoBrid. The total program budget now stands at $21.8M. NexoBrid is FDA-approved and supported by a $197M BARDA contract with Vericel (VCEL). MediWound's market cap is approximately $170M.
MediWound (MDWD) reported that a DSMB review recommended continuing the Phase III VALUE study of EscharEx for venous leg ulcers without modifications, citing no safety concerns. The trial aims to enroll 216 patients, with completion expected by Q1 2027. MDWD's stock closed at $13.11 on September 11, 2026, and is up 2.21% in pre-market trading.
MediWound (MDWD) reported Q2 2026 progress in its EscharEx VALUE phase III trial and record U.S. sales for NexoBrid. The company said full-year revenue guidance of $24–$26 million was reaffirmed, while revenue fell year over year due to BARDA contract timing, with growth expected in H2 from government contracts and new programs.
MediWound Ltd. (MDWD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under it
SHAMIR NACHUM purchased 6,000 shares of MediWound Ltd. (MDWD) at an average of $14.00 ($13.98–$14.00) across 2 trades on 2026-06-03.
Fox David Morton purchased 3,537 shares of MediWound Ltd. (MDWD) at an average of $14.11 ($14.00–$14.23) across 3 trades on 2026-06-01.
Rubinstein Samuel purchased 150 shares of MediWound Ltd. (MDWD) at $14.33 on 2026-05-29.
MediWound (MDWD) delivered earnings and revenue surprises of +70.37% and -15.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Ongoing Enrollment Continues in VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers ...
